LambdaVision Wins NASA Award to Develop Artificial Retina

More Images
FARMINGTON, Conn.—LambdaVision, a biotech developing a novel treatment to help patients regain sight, along with implementation partner Space Tango, has been selected by NASA for an award of $5 million. This new funding will support LambdaVision’s development of the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight due to advanced retinitis pigmentosa (RP), with follow-on applications in age-related macular degeneration (AMD), the leading cause of blindness for adults over 55 years old. As part of this award, the company, together with Space Tango, will explore the benefits of microgravity for producing LambdaVision’s artificial retina on the International Space Station (ISS) U.S. National Laboratory located in low-Earth orbit (LEO).

The contract will cover a series of flights to the ISS over three years to evaluate and improve on-orbit production processes, and to produce artificial retinas that will then be evaluated on Earth for the potential to restore vision to patients suffering from retinal degenerative diseases. Once validated, this process could also provide the foundation for a number of products that could be manufactured in space with clinical benefit to patients and process improvement across technology industries on Earth.

“Partnering with Space Tango and working closely with NASA continues to be an impactful experience that is providing new insight in the development of our artificial retina, and we are confident that this work will one day benefit patients who have lost their sight,” said Jordan Greco, PhD, chief scientific officer, LambdaVision. “It is also our hope that LambdaVision’s work will inspire new research and commercial product development that can help foster a thriving low-Earth orbit economy.”